梯瓦制药 TEVA 深沪

等待开盘 10-01 09:30:00 美东时间

39.60

-0.210

-0.53%

华盛通

立即下载

最高40.275
今开40.20
成交量 565.47万股
最低 39.22
昨收 39.81
总市值 461.85亿
52周最高 40.79
市盈率 ^静 32.66
换手率 0.48%
52周最低 18.825
委比 8.47%
总股本 11.66亿
历史最高 69.428
量比 0.98
振幅 2.65%
历史最低 6.07
每手 1
风险率 5.18%

个股概要

财务分析

公司资料

分红派息

分时图
日k
周k
月k

相关新闻

Teva names Serge Rogasik as CEO of API, CDMO business

Teva Pharmaceutical Industries appointed Serge Rogasik as CEO of TAPI (Technology & API Services), its active pharmaceutical ingredients and contract development and manufacturing organization divisio...

今天 05:26
Teva wins biosimilar approval of Amgen's Xgeva

The US FDA approved Teva Pharmaceutical Industries' (TEVA) Degvema (denosumab-adet), a biosimilar to Amgen's (AMGN) Xgeva (denosumab), which is indicated to prevent bone damage and complications in ca...

09-29 04:57
Teva Continues Biosimilar Momentum with U.S. FDA Approval of DEGEVMA™ (denosumab-adet), a Biosimilar to Xgeva® (denosumab)

Teva's DEGEVMA™ (denosumab-adet), a biosimilar to Xgeva® (denosumab), has received FDA approval for all indications, including preventing bone complications in adults with advanced cancer, treating bone giant cell tumors, and managing hypercalcemia of malignancy. This marks a significant milestone for Teva's Pivot to Growth strategy, enhancing access to affordable biologic treatments. DEGEVMA, alongside PONLIMSI™, forms a comprehensive denosumab ...

09-28 20:00
美股大行评级 | 汽车地带绩后遭10家机构降目标价！最低看至3000美元；美光、微软、Meta齐获看多

今日重点评级关注：Leerink Partners：维持塞德斯医疗"跑赢大市"评级，目标价从70美元升至88美元；HC Wainwright & Co.：维持TriSalus Life Sciences"买入"评级，目标价从11美元升至12美元

09-24 16:10
美股夜盘 | Unity Software大升5.67%，Everpure上升4.87%

Unity Software大升5.67%；Everpure上升4.87%；UDR不动产信托上升3.85%

09-24 15:01
内部人交易｜梯瓦制药披露一笔股票减持，金额约10.58万美元

美股上市公司梯瓦制药（TEVA）披露一笔内部人股票交易。文件显示，公司内部人Savage (Brian)（Officer）2026-09-18减持公司股票，交易...

09-24 07:02
Viatris, Teva initiated at Outperform at Oppenheimer

Oppenheimer began coverage of Viatris (VTRS) and Teva Pharmaceutical Industries (TEVA) with Outperform ratings for both. The price target for Viatris is $25 (~46% upside based on Sept. 22 close), whil...

09-24 00:12
Oppenheimer Initiates Coverage On Teva Pharmaceutical Indus with Outperform Rating, Announces Price Target of $50

Oppenheimer analyst Les Sulewski initiates coverage on Teva Pharmaceutical Indus (NYSE:TEVA) with a Outperform rating and announces Price Target of $50.

09-23 20:08
【机构持仓】先锋领航资本管理增持梯瓦制药

最新披露的机构持仓数据显示，先锋领航资本管理于最新季度调整了对梯瓦制药（TEVA）的持仓。主要变动如下：持仓变化：增持5049股仓位变化幅度：0.02...

09-17 15:21
梯瓦：仿制药出海浪潮中的耀眼新星

（来源：中国医药报）转自：中国医药报除了中枢神经系统和呼吸系统用药，梯瓦具有特色的创新药产品线主要集中在妇科领域。这些产品主要通过收购默克雪兰诺的妇科药物...

09-17 08:09

派息除权日	每股总股息	派息日期
2017-11-28	0.09	2017-12-12
2017-11-27	0.07	2017-12-12
2017-08-25	0.07	2017-09-14
2017-06-01	0.29	2017-06-22
2017-02-28	0.29	2017-03-20
2016-12-01	0.29	2016-12-20
2016-08-18	0.29	2016-09-08
2016-05-20	0.29	2016-06-07
2016-02-25	0.29	2016-03-14
2015-11-13	0.29	2015-12-03
2015-08-18	0.29	2015-09-03
2015-05-15	0.29	2015-06-04
2015-02-17	0.29	2015-03-03
2014-11-13	0.27	2014-12-02
2014-08-19	0.29	2014-09-04
2014-05-16	0.30	2014-06-02
2014-02-20	0.29	2014-03-10
2013-11-18	0.28	2013-12-03
2013-08-16	0.27	2013-09-03
2013-05-16	0.27	2013-06-03
2013-02-19	0.27	2013-03-07
2012-11-13	0.20	2012-12-03
2012-08-13	0.21	2012-09-04
2012-05-17	0.20	2012-06-04
2012-02-23	0.20	2012-03-15
2011-11-09	0.17	2011-12-07
2011-08-04	0.20	2011-08-25
2011-05-19	0.20	2011-06-07
2011-02-10	0.22	2011-03-07
2010-11-08	0.17	2010-12-06
2010-08-02	0.17	2010-08-26
2010-05-10	0.16	2010-06-04
2010-02-19	0.16	2010-03-17
2009-11-06	0.13	2009-12-04
2009-08-03	0.12	2009-08-27
2009-05-08	0.12	2009-06-03
2009-02-23	0.11	2009-03-19
2008-11-07	0.09	2008-12-05
2008-08-01	0.10	2008-08-27
2008-05-13	0.11	2008-06-05
2008-02-15	0.10	2008-03-13
2007-11-02	0.08	2007-11-28
2007-08-10	0.08	2007-09-06
2007-05-10	0.08	2007-06-05
2007-02-16	0.08	2007-03-15
2006-11-10	0.07	2006-12-06
2006-08-11	0.06	2006-09-08
2006-05-12	0.06	2006-06-07
2006-03-06	0.06	2006-03-30
2005-11-10	0.05	2005-12-07
2005-08-11	0.05	2005-09-07
2005-05-05	0.06	2005-06-01
2005-02-17	0.06	2005-03-17
2004-11-09	0.04	2004-12-06
2004-08-09	0.04	2004-09-07
2004-05-10	0.15	2004-06-07
2004-02-20	0.08	2004-03-22
2003-11-13	0.06	2003-12-12
2003-08-08	0.06	2003-09-08
2003-05-08	0.06	2003-06-06
2003-02-24	0.05	2003-03-24
2002-11-07	0.07	2002-12-06
2002-08-19	0.07	2002-09-16
2002-05-20	0.07	2002-06-17
2002-02-15	0.08	2002-03-18
2001-11-16	0.05	2001-12-17
2001-08-20	0.05	2001-09-17
2001-05-17	0.05	2001-06-15
2001-03-08	0.05	2001-04-06
2000-11-16	0.04	2000-12-15
2000-08-24	0.04	2000-09-21
2000-05-19	0.04	2000-06-19
2000-02-17	0.08	2000-03-27
1999-11-04	0.05	1999-11-30
1999-08-18	0.05	1999-09-13
1999-05-21	0.05	1999-06-15
1999-03-08	0.05	1999-03-30
1998-11-20	0.05	1998-12-11
1998-08-21	0.06	1998-09-11
1998-05-21	0.06	1998-06-22
1998-03-12	0.06	1998-03-31
1997-11-20	0.07	1997-12-09
1997-08-25	0.07	1997-09-11
1997-05-23	0.07	1997-06-12
1997-03-07	0.07	1997-03-26
1996-11-20	0.05	1996-12-09
1996-08-26	0.05	1996-09-12
1996-05-23	0.05	1996-06-12
1996-03-07	0.05	1996-03-26
1995-11-20	0.05	1995-12-07
1995-08-14	0.05	1995-08-30
1995-05-17	0.05	1995-06-07
1995-03-07	0.05	1995-04-04
1994-11-15	0.05	1994-12-13
1994-08-09	0.05	1994-09-12
1994-05-18	0.05	1994-06-21
1994-03-08	0.05	1994-04-05
1993-11-17	0.04	1994-01-03
1993-08-17	0.04	1993-09-14
1993-05-18	0.03	1993-06-21
1993-04-07	0.06	1993-05-05
1992-11-17	0.04	1992-12-21
1992-08-18	0.04	1992-09-21
1991-11-20	0.04	1991-12-19
1991-08-20	0.04	1991-09-19
1991-05-19	0.04	1991-07-19
1991-03-05	0.04	1991-03-28
1990-11-20	0.04	1990-12-20
1990-08-16	0.04	1990-09-17
1989-05-21	0.04	1989-06-18
1988-12-06	0.04	1988-12-30
1988-09-07	0.04	1988-10-05
1988-06-09	0.03	1988-07-19
1988-04-11	0.03	1988-05-15
1988-02-08	0.03	1988-03-10
1987-10-23	0.03	1987-11-19
1987-07-08	0.04	1987-08-04
1987-06-21	0.03	1987-07-13
1987-02-23	0.03	1987-03-26
1985-09-23	0.02	1985-10-21
1985-06-17	0.02	1985-07-15
1984-01-27	0.02	1984-02-29
1982-08-16	0.40	1982-09-13
1982-08-10	0.06	1982-09-13

公司名称	梯瓦制药
行业分类	制药
业务描述	Teva Pharmaceutical Industries Ltd. engages in the development, production, and sale of medicines. It operates through the following geographical segments: United States, Europe, and International Markets. The United States segment focuses on therapeutic area of central nervous system (CNS) portfolio, and is involved in the distribution business of generic, biosimilar and medicines, and over-the-counter (OTC) pharmaceutical products from the firm and third-party manufacturers to independent retail pharmacies, pharmacy retail chains, hospitals, and physician offices in the United States. The Europe segment offers OTC portfolio including SUDOCREM, NasenDuo, DICLOX FORTE, OLFEN Max, and FLEGAMINA brands in European Union, the United Kingdom, and certain other European countries. The International Markets segment provides its products to countries such as Canada, Israel, Russia, Latin America, and Japan. The company was founded in 1901 and is headquartered in Tel Aviv, Israel.

梯瓦制药 TEVA 深 沪

39.60

个股概要

财务分析

公司资料

相关新闻

分红派息

相关新闻

公司简介

梯瓦制药 TEVA 深沪